A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of Anticoagulation with Low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT). - ALICAT

Cardiff University0 个研究点目标入组 5 人开始时间: 2013年3月14日最近更新: 2019年6月30日

试验速览

暂无简介。

•1. Receiving LMWH for treatment of CAT for five months; 2. Locally advanced or metastatic cancer; 3. Able to self-administer LMWH, or have LMWH administered by a carer; 4. Able to give informed consent; 5. Age =16 years.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 5
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•1.Receiving drug other than LMWH for CAT; 2.Contraindication to anticoagulation; a. known allergies to LMWHs, heparin, sulfites or benzyl alcohol, b. active major bleeding c. history of heparin-induced thrombocytopenia 3. Confirmed recurrent VTE whilst receiving anticoagulation; 4. Fitted with a prosthetic heart valve; 5. Pregnant and/or lactating females.

发起方